REPH - Recro Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue77,34771,83469,33751,952
Cost of Revenue83,14570,52270,43040,335
Gross Profit-5,7981,312-1,09311,617
Operating Expenses
Research Development39,98539,98539,98539,985
Selling General and Administrative36,87925,42612,74213,017
Non Recurring----
Others----
Total Operating Expenses122,60798,53185,75555,236
Operating Income or Loss-45,260-26,697-16,418-3,284
Income from Continuing Operations
Total Other Income/Expenses Net-17,027-25,263-14,894-9,234
Earnings Before Interest and Taxes-45,260-26,697-16,418-3,284
Interest Expense-8,756-12,034-5,588-5,560
Income Before Tax-62,287-51,960-31,312-12,518
Income Tax Expense17,436-1,880-1,107-15,551
Minority Interest----
Net Income From Continuing Ops-79,723-50,080-30,2053,033
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-79,723-50,080-30,2053,033
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-79,723-50,080-30,2053,033